TY - JOUR
T1 - Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi
AU - Arcari, A.
AU - Morello, L.
AU - Vallisa, D.
AU - Marcheselli, L.
AU - Tecchio, C.
AU - Quaglia, F.M.
AU - Tisi, M.C.
AU - Zilioli, V.R.
AU - Di Rocco, A.
AU - Perrone, T.
AU - Gini, G.
AU - Dogliotti, I.
AU - Bianchetti, N.
AU - Bozzoli, V.
AU - De Philippis, C.
AU - Alvarez De Celis, M.I.
AU - Chiappella, A.
AU - Fabbri, A.
AU - Pelosini, M.
AU - Merli, M.
AU - Molinari, A.L.
AU - Sciarra, R.
AU - Volpetti, S.
AU - Hohaus, S.
AU - Nassi, L.
AU - Visco, C.
N1 - Export Date: 15 February 2022
PY - 2021/12
Y1 - 2021/12
N2 - The role of allogeneic stem cell transplantation (allo-SCT) in mantle cell lymphoma (MCL) is uncertain, even more in the era of bruton’s tyrosine kinase inhibitors (BTKi) and chimeric antigen receptor T-cells. We retrospectively analyzed 55 patients who underwent allo-SCT for MCL relapsed or refractory (r/r) after rituximab and high-dose cytarabine within the MANTLE-FIRST project. With a median follow-up of 3.7 years, non-relapse mortality (NRM), progression-free survival, and overall survival were 23%, 53%, and 56%, respectively. NRM was significantly higher in the case of acute graft-versus-host disease, > 2 prior lines of therapy, age > 60 years. The outcome was similar for patients with early (≤24 months) and late progression of disease. The use of BTKi as a bridge to allo-SCT did not increase the toxicity and allowed a good control of disease. Our real-life experience confirms that allo-SCT still represents an option in MCL patients, especially if young and early-relapsed.
AB - The role of allogeneic stem cell transplantation (allo-SCT) in mantle cell lymphoma (MCL) is uncertain, even more in the era of bruton’s tyrosine kinase inhibitors (BTKi) and chimeric antigen receptor T-cells. We retrospectively analyzed 55 patients who underwent allo-SCT for MCL relapsed or refractory (r/r) after rituximab and high-dose cytarabine within the MANTLE-FIRST project. With a median follow-up of 3.7 years, non-relapse mortality (NRM), progression-free survival, and overall survival were 23%, 53%, and 56%, respectively. NRM was significantly higher in the case of acute graft-versus-host disease, > 2 prior lines of therapy, age > 60 years. The outcome was similar for patients with early (≤24 months) and late progression of disease. The use of BTKi as a bridge to allo-SCT did not increase the toxicity and allowed a good control of disease. Our real-life experience confirms that allo-SCT still represents an option in MCL patients, especially if young and early-relapsed.
U2 - 10.1080/10428194.2021.1961238
DO - 10.1080/10428194.2021.1961238
M3 - Article
SN - 1042-8194
VL - 62
SP - 3474
EP - 3483
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 14
ER -